Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Patients with/without EGFR-Mutation: Evidence Based on Recent Phase III Randomized Trials

BACKGROUND: EGFR mutation might be a predictive factor for applying EGFR-tyrosine kinase inhibitors (EGFR-TKIs, including gefitinib, erlotinib and afatinib) in non-small-cell lung cancer (NSCLS) patients. Thus, it is necessary to pool previous trials to compare the effect of EGFR-TKIs versus cytotox...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wen-Qian, Li, Tong, Li, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2014
Materias:
Special Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271800/
https://www.ncbi.nlm.nih.gov/pubmed/25503781
http://dx.doi.org/10.12659/MSM.892476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271800/
https://www.ncbi.nlm.nih.gov/pubmed/25503781
http://dx.doi.org/10.12659/MSM.892476

Ejemplares similares